Movano (NASDAQ:MOVE) versus Pulmonx (NASDAQ:LUNG) Critical Survey

Pulmonx (NASDAQ:LUNG) and Movano (NASDAQ:MOVE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional & Insider Ownership

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 16.6% of Movano shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by insiders. Comparatively, 13.4% of Movano shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Pulmonx and Movano’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	-65.27%	-63.69%	-34.94%
Movano	N/A	-288.42%	-181.30%

Volatility & Risk

Pulmonx has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Movano has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Pulmonx and Movano, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	3	5	0	2.63
Movano	0	0	1	0	3.00

Pulmonx currently has a consensus price target of $11.53, suggesting a potential upside of 319.09%. Movano has a consensus price target of $30.00, suggesting a potential upside of 3,796.10%. Given Movano’s stronger consensus rating and higher probable upside, analysts plainly believe Movano is more favorable than Pulmonx.

Earnings and Valuation

This table compares Pulmonx and Movano”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$83.79 million	1.32	-$56.39 million	($1.44)	-1.91
Movano	$1.01 million	5.37	-$23.73 million	($4.07)	-0.19

Movano has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Movano, indicating that it is currently the more affordable of the two stocks.

Summary

Movano beats Pulmonx on 8 of the 14 factors compared between the two stocks.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

About Movano

Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.